Congress: Movement Disorder Society (MDS) International Congress 2026
Dates: October 4-8, 2026
Location: Seoul, Korea — COEX Convention and Exhibition Center
Theme: Understanding Aging in Movement Disorders
The MDS 2026 congress will feature sessions on rare movement disorders, a diverse group of neurological conditions that include genetic, metabolic, and acquired etiologies. These disorders often present unique diagnostic and therapeutic challenges.
- SCA1, SCA2, SCA3, SCA6, etc.: Genotype-phenotype correlations and therapeutic approaches
- Gene-Specific Therapies: Antisense oligonucleotides for SCA1, SCA3
- Vitamin and Metabolic Approaches: CoQ10, vitamin E, metabolic supplementation
- Frataxin Restoration: Gene therapy and protein replacement approaches
- Iron-Sulfur Cluster Biogenesis: Mitochondrial function restoration
- Antioxidant Therapies: CoQ10, idebenone, EPI-743
- DYT1 (TOR1A): Early-onset generalized dystonia
- DYT5 (GCH1): Dopa-responsive dystonia
- DYT16 (PRKRA): Young-onset dystonia-parkinsonism
- DYT11 (SGCE): Myoclonus-dystonia
- Deep Brain Stimulation: GPi and thalamic targets
- Botulinum Toxin Injections: Focal dystonia management
- Oral Medications: Anticholinergics, baclofen, benzodiazepines
- ATP7B Gene Therapy: Emerging genetic treatments
- Copper Chelation: Trientine, penicillamine alternatives
- Zinc Therapy: Maintenance and prevention
- Liver Transplantation: For hepatic failure
- PKAN (PANK2): Pantothenate kinase-associated neurodegeneration
- FA2H, WDR45, COASY: Other NBIA subtypes
- Iron Chelation: Deferoxamine, deferasirox
- Menkes Disease: Copper transport defect
- Aceruloplasminemia: Iron overload with neurodegeneration
- Hereditary Hemochromatosis: Iron accumulation
- Paroxysmal Dyskinesias: PKD, PNKD, PED
- Episodic Ataxia: EA1, EA2
- Channelopathies: Ion channel dysfunction
- AAV Vector Delivery: Adeno-associated virus-based gene replacement
- CRISPR Gene Editing: Precise genetic correction
- RNA Therapeutics: ASOs and siRNA
- Molecular Chaperones: Protein folding correction
- Enzyme Replacement: Metabolic pathway restoration
- Receptor Modulators: Targeting specific neurotransmitter systems
- Stem Cell Transplantation: Neural progenitor cells
- Cell Replacement: Specific neuronal populations